Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys

Peter Abbink(Beth Israel Deaconess Medical Center), Rafael A. Larocca(Beth Israel Deaconess Medical Center), Rafael A. De La Barrera(Walter Reed Army Institute of Research), Christine A. Bricault(Beth Israel Deaconess Medical Center), Edward T. Moseley(Beth Israel Deaconess Medical Center), Michael Boyd(Beth Israel Deaconess Medical Center), Marinela Kirilova(Beth Israel Deaconess Medical Center), Zhenfeng Li(Beth Israel Deaconess Medical Center), David Ng’ang’a(Beth Israel Deaconess Medical Center), Ovini Nanayakkara(Beth Israel Deaconess Medical Center), Ramya Nityanandam(Beth Israel Deaconess Medical Center), Noe B. Mercado(Beth Israel Deaconess Medical Center), Erica N. Borducchi(Beth Israel Deaconess Medical Center), Arshi Agarwal(Beth Israel Deaconess Medical Center), Amanda Brinkman(Beth Israel Deaconess Medical Center), Crystal Cabral(Beth Israel Deaconess Medical Center), Abishek Chandrashekar(Beth Israel Deaconess Medical Center), Patricia Giglio(Beth Israel Deaconess Medical Center), David Jetton(Beth Israel Deaconess Medical Center), Jessica Jimenez(Beth Israel Deaconess Medical Center), Benjamin C. Lee(Beth Israel Deaconess Medical Center), Shanell Mojta(Beth Israel Deaconess Medical Center), Katherine Molloy(Beth Israel Deaconess Medical Center), Mayuri Shetty(Beth Israel Deaconess Medical Center), George H. Neubauer(Beth Israel Deaconess Medical Center), Kathryn E. Stephenson(Beth Israel Deaconess Medical Center), Jean Pierre Schatzmann Peron(Universidade de São Paulo), Paolo Marinho de Andrade Zanotto(Universidade de São Paulo), Johnathan Misamore(Bioqual), Brad Finneyfrock(Bioqual), Mark G. Lewis(Bioqual), Galit Alter(Ragon Institute of MGH, MIT and Harvard), Kayvon Modjarrad(Henry M. Jackson Foundation), Richard G. Jarman(Walter Reed Army Institute of Research), Kenneth H. Eckels(Walter Reed Army Institute of Research), Nelson L. Michael(Walter Reed Army Institute of Research), Stephen J. Thomas(Walter Reed Army Institute of Research), Dan H. Barouch(Beth Israel Deaconess Medical Center)
Science
August 4, 2016
10.1126/science.aah6157
Cited by 504Open Access
Full Text

Abstract

Zika virus (ZIKV) is responsible for a major ongoing epidemic in the Americas and has been causally associated with fetal microcephaly. The development of a safe and effective ZIKV vaccine is therefore an urgent global health priority. Here we demonstrate that three different vaccine platforms protect against ZIKV challenge in rhesus monkeys. A purified inactivated virus vaccine induced ZIKV-specific neutralizing antibodies and completely protected monkeys against ZIKV strains from both Brazil and Puerto Rico. Purified immunoglobulin from vaccinated monkeys also conferred passive protection in adoptive transfer studies. A plasmid DNA vaccine and a single-shot recombinant rhesus adenovirus serotype 52 vector vaccine, both expressing ZIKV premembrane and envelope, also elicited neutralizing antibodies and completely protected monkeys against ZIKV challenge. These data support the rapid clinical development of ZIKV vaccines for humans.

Related Papers

No related papers found

Powered by citation graph analysis